Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences has reported a change in Director David Atkins’ interests in the company’s securities, following the lapse of 2,000,000 unlisted options held directly and indirectly, including via Beacon Advisors Ltd. After this change, Atkins retains his existing ordinary shares, loan funded shares, listed options, and deferred shares, but his unlisted options have decreased to 2,466,820, reflecting an adjustment in his long-term incentive exposure rather than an on-market transaction.
The update, lodged under ASX disclosure rules, is an administrative notification that clarifies the current structure of a key director’s equity and option holdings in the business. While it does not involve any cash consideration or trading activity, the reduction in unlisted options slightly reshapes the director’s potential future equity participation and provides shareholders with greater transparency over board-level incentives.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited is an Australian-listed biotechnology company focused on developing and commercialising diagnostic technologies. The company’s activities typically centre on innovative medical testing solutions aimed at improving disease detection and patient outcomes in healthcare markets.
Average Trading Volume: 986,412
Technical Sentiment Signal: Buy
Current Market Cap: A$65.59M
See more data about RHY stock on TipRanks’ Stock Analysis page.